Soligenix axes lymphoma program after phase 3 setback, mulls M&A options

Soligenix has scrapped its cutaneous T-cell lymphoma program in the wake of a phase 3 setback, leaving the biotech focused on another rare disease prospect and considering strategic alternatives.